Park Avenue Securities LLC Buys 7,103 Shares of Novo Nordisk A/S (NYSE:NVO)

Park Avenue Securities LLC raised its position in Novo Nordisk A/S (NYSE:NVO) by 7.4% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 102,657 shares of the company’s stock after purchasing an additional 7,103 shares during the period. Park Avenue Securities LLC’s holdings in Novo Nordisk A/S were worth $8,831,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Strategic Investment Solutions Inc. IL bought a new position in Novo Nordisk A/S during the second quarter worth about $25,000. Daiwa Securities Group Inc. purchased a new stake in Novo Nordisk A/S in the third quarter valued at approximately $28,000. Capital Performance Advisors LLP purchased a new stake in Novo Nordisk A/S in the third quarter worth approximately $42,000. Carolina Wealth Advisors LLC bought a new position in Novo Nordisk A/S during the 3rd quarter worth approximately $48,000. Finally, M&R Capital Management Inc. grew its holdings in Novo Nordisk A/S by 260.5% in the 3rd quarter. M&R Capital Management Inc. now owns 411 shares of the company’s stock worth $49,000 after acquiring an additional 297 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 2.2 %

NYSE NVO opened at $82.99 on Thursday. The company has a fifty day moving average of $99.26 and a 200 day moving average of $118.18. The company has a market capitalization of $372.42 billion, a PE ratio of 26.86, a P/E/G ratio of 1.37 and a beta of 0.45. Novo Nordisk A/S has a 1 year low of $80.05 and a 1 year high of $148.15. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on NVO shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. BMO Capital Markets decreased their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Finally, UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $140.20.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.